Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 301

1.

Immune profiling and quantitative analysis decipher the clinical role of immune checkpoint expression in the tumor immune microenvironment of DLBCL.

Xu-Monette Z, Xiao M, Au Q, Padmanabhan R, Xu B, Hoe N, Rodriguez-Perales S, Torres-Ruiz R, Manyam G, Visco C, Miao Y, Tan X, Zhang H, Tzankov A, Wang J, Dybkaer K, Tam W, You H, Bhagat G, Hsi ED, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, van Krieken JH, Winter JN, Westin JR, Pham LV, Medeiros LJ, Rassidakis GZ, Li Y, Freeman GJ, Young KH.

Cancer Immunol Res. 2019 Feb 11. pii: canimm.0439.2018. doi: 10.1158/2326-6066.CIR-18-0439. [Epub ahead of print]

PMID:
30745366
2.

Serum levels of TARC, MDC, IL10 and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study.

Hsi ED, Li H, Nixon AB, Schöder H, Bartlett NL, LeBlanc M, Smith S, Kahl BS, Leonard JP, Evens AM, Scott DW, Rimsza LM, Friedberg JW.

Blood. 2019 Feb 5. pii: blood-2018-08-870915. doi: 10.1182/blood-2018-08-870915. [Epub ahead of print]

PMID:
30723079
3.

Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma.

O'Connor OA, Özcan M, Jacobsen ED, Roncero JM, Trotman J, Demeter J, Masszi T, Pereira J, Ramchandren R, Beaven A, Caballero D, Horwitz SM, Lennard A, Turgut M, Hamerschlak N, d'Amore FA, Foss F, Kim WS, Leonard JP, Zinzani PL, Chiattone CS, Hsi ED, Trümper L, Liu H, Sheldon-Waniga E, Ullmann CD, Venkatakrishnan K, Leonard EJ, Shustov AR; Lumiere Study Investigators.

J Clin Oncol. 2019 Feb 1:JCO1800899. doi: 10.1200/JCO.18.00899. [Epub ahead of print]

PMID:
30707661
4.

The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.

Park SI, Horwitz SM, Foss FM, Pinter-Brown LC, Carson KR, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Shustov AR.

Cancer. 2019 Jan 29. doi: 10.1002/cncr.31861. [Epub ahead of print]

PMID:
30694529
5.

PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program.

Li L, Sun R, Miao Y, Tran T, Adams L, Roscoe N, Xu B, Manyam GC, Tan X, Zhang H, Xiao M, Tzankov A, Visco C, Dybkaer K, Bhagat G, Tam W, Hsi ED, van Krieken JH, You H, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, Zhang M, Winter JN, Medeiros LJ, Rassidakis GZ, Vaupel CA, Li Y, Dakappagari N, Xu-Monette ZY, Young KH.

Mod Pathol. 2019 Jan 21. doi: 10.1038/s41379-018-0193-5. [Epub ahead of print]

PMID:
30666052
6.

Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy.

Landsburg DJ, Hughes ME, Koike A, Bond D, Maddocks KJ, Guo L, Winter AM, Hill BT, Ondrejka SL, Hsi ED, Nasta SD, Svoboda J, Schuster SJ, Bogusz AM.

Blood Adv. 2019 Jan 22;3(2):132-135. doi: 10.1182/bloodadvances.2018026401. No abstract available.

7.

The current role of clinical flow cytometry in the evaluation of mature B-cell neoplasms.

Seegmiller AC, Hsi ED, Craig FE.

Cytometry B Clin Cytom. 2019 Jan;96(1):20-29. doi: 10.1002/cyto.b.21756. Epub 2018 Dec 13. Review.

PMID:
30549186
8.

CCND2 and CCND3 hijack immunoglobulin light chain enhancers in cyclin D1-negative mantle cell lymphoma.

Martín-Garcia D, Navarro A, Valdés-Mas R, Clot G, Gutiérrez-Abril J, Prieto M, Ribera-Cortada I, Woroniecka R, Rymkiewicz G, Bens S, de Leval L, Rosenwald A, Ferry JA, Hsi ED, Fu K, Delabie J, Weisenburger D, de Jong D, Climent F, O'Connor SJ, Swerdlow SH, Torrents D, Beltran S, Espinet B, González-Farré B, Veloza L, Costa D, Matutes E, Siebert R, Ott G, Quintanilla-Martinez L, Jaffe ES, López-Otín C, Salaverria I, Puente XS, Campo E, Beà S.

Blood. 2018 Dec 11. pii: blood-2018-07-862151. doi: 10.1182/blood-2018-07-862151. [Epub ahead of print]

PMID:
30538135
9.

Intensive immunochemotherapy for high-risk aggressive B-cell lymphomas: MYC-rearrangements and beyond.

Hsi ED.

Lancet Haematol. 2018 Dec;5(12):e600-e601. doi: 10.1016/S2352-3026(18)30193-5. No abstract available.

PMID:
30501862
10.

Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016.

Qu X, Li H, Braziel RM, Passerini V, Rimsza LM, Hsi ED, Leonard JP, Smith SM, Kridel R, Press O, Weigert O, LeBlanc M, Friedberg JW, Fang M.

Blood. 2019 Jan 3;133(1):81-93. doi: 10.1182/blood-2018-07-865428. Epub 2018 Nov 16.

PMID:
30446494
11.

Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study.

Tang G, Sydney Sir Philip JK, Weinberg O, Tam W, Sadigh S, Lake JI, Margolskee EM, Rogers HJ, Miranda RN, Bueso-Ramos C C, Hsi ED, Orazi A, Hasserjian RP, Arber DA, Bagg A, Wang SA.

Mod Pathol. 2018 Nov 6. doi: 10.1038/s41379-018-0165-9. [Epub ahead of print]

PMID:
30401948
12.

Composite chronic myeloid leukemia and essential thrombocythemia with BCR-ABL1 fusion and CALR mutation.

Xia D, Hsi ED, Cin PD, Hasserjian RP.

Am J Hematol. 2018 Aug 13. doi: 10.1002/ajh.25249. [Epub ahead of print] No abstract available.

PMID:
30105753
13.

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.

Straus DJ, Jung SH, Pitcher B, Kostakoglu L, Grecula JC, Hsi ED, Schöder H, Popplewell LL, Chang JE, Moskowitz CH, Wagner-Johnston N, Leonard JP, Friedberg JW, Kahl BS, Cheson BD, Bartlett NL.

Blood. 2018 Sep 6;132(10):1013-1021. doi: 10.1182/blood-2018-01-827246. Epub 2018 Jul 26.

PMID:
30049811
14.

CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia.

Jiang YP, Liu BY, Zheng Q, Panuganti S, Chen R, Zhu J, Mishra M, Huang J, Dao-Pick T, Roy S, Zhao X, Lin J, Banik G, Hsi ED, Mandalam R, Junutula JR.

Blood Adv. 2018 Jul 24;2(14):1738-1749. doi: 10.1182/bloodadvances.2018020107.

15.

SLAMF7 (CD319/CS1) is expressed in plasmablastic lymphoma and is a potential diagnostic marker and therapeutic target.

Shi J, Bodo J, Zhao X, Durkin L, Goyal T, Meyerson H, Hsi ED.

Br J Haematol. 2018 May 22. doi: 10.1111/bjh.15393. [Epub ahead of print] No abstract available.

PMID:
29785767
16.

JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group.

Aynardi J, Manur R, Hess PR, Chekol S, Morrissette JJD, Babushok D, Hexner E, Rogers HJ, Hsi ED, Margolskee E, Orazi A, Hasserjian R, Bagg A.

Br J Haematol. 2018 Jul;182(1):78-85. doi: 10.1111/bjh.15276. Epub 2018 May 16.

PMID:
29767839
17.

LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates.

Purcell JW, Tanlimco SG, Hickson J, Fox M, Sho M, Durkin L, Uziel T, Powers R, Foster K, McGonigal T, Kumar S, Samayoa J, Zhang D, Palma JP, Mishra S, Hollenbaugh D, Gish K, Morgan-Lappe SE, Hsi ED, Chao DT.

Cancer Res. 2018 Jul 15;78(14):4059-4072. doi: 10.1158/0008-5472.CAN-18-0327. Epub 2018 May 15.

PMID:
29764866
18.

Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma.

Wang X, Cao X, Sun R, Tang C, Tzankov A, Zhang J, Manyam GC, Xiao M, Miao Y, Jabbar K, Tan X, Pang Y, Visco C, Xie Y, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WWL, van Krieken JH, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, Winter JN, Piris MA, Li S, Miranda RN, Medeiros LJ, Li Y, Xu-Monette ZY, Young KH.

Neoplasia. 2018 Jun;20(6):574-593. doi: 10.1016/j.neo.2018.03.002. Epub 2018 May 4.

19.

MYD88 L265P Mutation in Lymphoid Malignancies.

Yu X, Li W, Deng Q, Li L, Hsi ED, Young KH, Zhang M, Li Y.

Cancer Res. 2018 May 15;78(10):2457-2462. doi: 10.1158/0008-5472.CAN-18-0215. Epub 2018 Apr 27. Review.

PMID:
29703722
20.

Immunohistochemical Analysis of Endothelial Cells in Vascular Transformation of Lymph Node Sinuses: Vascular or Lymphatic Differentiation?

Basha BM, Hsi ED.

Appl Immunohistochem Mol Morphol. 2018 Apr 7. doi: 10.1097/PAI.0000000000000661. [Epub ahead of print]

PMID:
29629951
21.

Co-expression of MYC and BCL2 predicts poorer outcomes for relapsed/refractory diffuse large B-cell lymphoma with R-ICE and intent to transplant.

Allen J, Ruano Mendez AL, Rybicki L, Sawalha Y, Jagadeesh D, Dean R, Pohlman B, Smith MR, Hsi ED, Hill BT.

Ther Adv Hematol. 2018 Apr;9(4):81-87. doi: 10.1177/2040620718759249. Epub 2018 Mar 29.

22.

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.

Czuczman MS, Leonard JP, Jung S, Johnson JL, Hsi ED, Byrd JC, Cheson BD.

Ann Oncol. 2018 Nov 1;29(11):2271. doi: 10.1093/annonc/mdx812. No abstract available.

23.

T-Cell Large Granular Lymphocytic Leukemia and Coexisting B-Cell Lymphomas: A Study From the Bone Marrow Pathology Group.

Goyal T, Thakral B, Wang SA, Bueso-Ramos CE, Shi M, Jevremovic D, Morice WG, Zhang QY, George TI, Foucar KK, Bhattacharyya S, Bagg A, Rogers HJ, Bodo J, Durkin L, Hsi ED.

Am J Clin Pathol. 2018 Jan 29;149(2):164-171. doi: 10.1093/ajcp/aqx146.

PMID:
29365010
24.

Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.

Soderquist CR, Ewalt MD, Czuchlewski DR, Geyer JT, Rogers HJ, Hsi ED, Wang SA, Bueso-Ramos CE, Orazi A, Arber DA, Hexner EO, Babushok DV, Bagg A.

Mod Pathol. 2018 May;31(5):690-704. doi: 10.1038/modpathol.2017.182. Epub 2018 Jan 12.

PMID:
29327708
25.

Evaluation of PD1/PDL1 Expression and Their Clinicopathologic Association in EBV-associated Lymphoproliferative Disorders in Nonimmunosuppressed Patients.

Guo L, Bodo J, Durkin L, Hsi ED.

Appl Immunohistochem Mol Morphol. 2019 Feb;27(2):101-106. doi: 10.1097/PAI.0000000000000583.

PMID:
29084057
26.

Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.

Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, Leppa S, Pasanen A, Meriranta L, Karjalainen-Lindsberg ML, Nørgaard P, Pedersen M, Gang AO, Høgdall E, Heavican TB, Lone W, Iqbal J, Qin Q, Li G, Kim SY, Healy J, Richards KL, Fedoriw Y, Bernal-Mizrachi L, Koff JL, Staton AD, Flowers CR, Paltiel O, Goldschmidt N, Calaminici M, Clear A, Gribben J, Nguyen E, Czader MB, Ondrejka SL, Collie A, Hsi ED, Tse E, Au-Yeung RKH, Kwong YL, Srivastava G, Choi WWL, Evens AM, Pilichowska M, Sengar M, Reddy N, Li S, Chadburn A, Gordon LI, Jaffe ES, Levy S, Rempel R, Tzeng T, Happ LE, Dave T, Rajagopalan D, Datta J, Dunson DB, Dave SS.

Cell. 2017 Oct 5;171(2):481-494.e15. doi: 10.1016/j.cell.2017.09.027.

27.

Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations.

Visco C, Wang J, Tisi MC, Deng L, D'Amore ESG, Tzankov A, Montes-Moreno S, Dybkær K, Bhagat G, Hsi ED, van Krieken JH, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, Medeiros LJ, Xu-Monette ZY, Young KH.

Br J Cancer. 2017 Nov 21;117(11):1685-1688. doi: 10.1038/bjc.2017.345. Epub 2017 Sep 26.

28.

A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance).

Martin P, Jung SH, Pitcher B, Bartlett NL, Blum KA, Shea T, Hsi ED, Ruan J, Smith SE, Leonard JP, Cheson BD.

Ann Oncol. 2017 Nov 1;28(11):2806-2812. doi: 10.1093/annonc/mdx496.

29.

Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era.

Mustafa Ali M, Rybicki L, Nomani L, Rouphail B, Dean RM, Hill BT, Jagadeesh D, Pohlman B, Hsi ED, Smith MR.

Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):797-803. doi: 10.1016/j.clml.2017.07.002. Epub 2017 Jul 13.

PMID:
28789937
30.

Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.

Yao Z, Deng L, Xu-Monette ZY, Manyam GC, Jain P, Tzankov A, Visco C, Bhagat G, Wang J, Dybkaer K, Tam W, Hsi ED, van Krieken JH, Ponzoni M, Ferreri AJM, Møller MB, Winter JN, Piris MA, Fayad L, Liu Y, Song Y, Orlowski RZ, Kantarjian H, Medeiros LJ, Li Y, Cortes J, Young KH.

Leukemia. 2018 Feb;32(2):353-363. doi: 10.1038/leu.2017.222. Epub 2017 Jul 12.

31.

Orbital diffuse large B-cell lymphoma with combined variable immunodeficiency.

Parikh VS, Jagadeesh D, Fernandez JM, Hsi ED, Singh AD.

Orbit. 2017 Oct;36(5):340-343. doi: 10.1080/01676830.2017.1337170. Epub 2017 Jul 18.

PMID:
28718689
32.

AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma.

Wang J, Xu-Monette ZY, Jabbar KJ, Shen Q, Manyam GC, Tzankov A, Visco C, Wang J, Montes-Moreno S, Dybkær K, Tam W, Bhagat G, Hsi ED, van Krieken JH, Ponzoni M, Ferreri AJM, Wang S, Møller MB, Piris MA, Medeiros LJ, Li Y, Pham LV, Young KH.

Am J Pathol. 2017 Aug;187(8):1700-1716. doi: 10.1016/j.ajpath.2017.04.009. Epub 2017 Jun 13.

33.

Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome.

Wang SA, Hasserjian RP, Tam W, Tsai AG, Geyer JT, George TI, Foucar K, Rogers HJ, Hsi ED, Rea BA, Bagg A, Bueso-Ramos CE, Arber DA, Verstovsek S, Orazi A.

Haematologica. 2017 Aug;102(8):1352-1360. doi: 10.3324/haematol.2017.165340. Epub 2017 May 11.

34.

Assessment of semi-quantitative grading of red blood cell abnormalities utilizing images from the CellaVision DM96 compared to manual light microscopy.

Nakashima MO, Doyle TJ, Phelan-Lewin K, Summers JM, Bena J, Hsi ED.

Int J Lab Hematol. 2017 Oct;39(5):e110-e112. doi: 10.1111/ijlh.12673. Epub 2017 May 10. No abstract available.

PMID:
28488791
35.

2016 WHO Classification update-What's new in lymphoid neoplasms.

Hsi ED.

Int J Lab Hematol. 2017 May;39 Suppl 1:14-22. doi: 10.1111/ijlh.12650. Review.

PMID:
28447410
36.

Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2.

Moffitt AB, Ondrejka SL, McKinney M, Rempel RE, Goodlad JR, Teh CH, Leppa S, Mannisto S, Kovanen PE, Tse E, Au-Yeung RKH, Kwong YL, Srivastava G, Iqbal J, Yu J, Naresh K, Villa D, Gascoyne RD, Said J, Czader MB, Chadburn A, Richards KL, Rajagopalan D, Davis NS, Smith EC, Palus BC, Tzeng TJ, Healy JA, Lugar PL, Datta J, Love C, Levy S, Dunson DB, Zhuang Y, Hsi ED, Dave SS.

J Exp Med. 2017 May 1;214(5):1371-1386. doi: 10.1084/jem.20160894. Epub 2017 Apr 19.

37.

A flood of information from drops of blood.

Hsi ED.

Blood. 2017 Apr 6;129(14):1891-1893. doi: 10.1182/blood-2017-02-764647. No abstract available.

38.

Most Myeloid Neoplasms With Deletion of Chromosome 16q Are Distinct From Acute Myeloid Leukemia With Inv(16)(p13.1q22): A Bone Marrow Pathology Group Multicenter Study.

Rogers HJ, Hsi ED, Tang G, Wang SA, Bueso-Ramos CE, Lubin D, Morrissette JJ, Bagg A, Cherukuri DP, George TI, Peterson L, Liu YC, Mathew S, Orazi A, Hasserjian RP.

Am J Clin Pathol. 2017 Apr 1;147(4):411-419. doi: 10.1093/ajcp/aqx020.

PMID:
28375434
39.

Clinicopathologic and molecular characterization of myeloid neoplasms with isolated t(6;9)(p23;q34).

Visconte V, Shetty S, Przychodzen B, Hirsch C, Bodo J, Maciejewski JP, Hsi ED, Rogers HJ.

Int J Lab Hematol. 2017 Aug;39(4):409-417. doi: 10.1111/ijlh.12641. Epub 2017 Mar 20.

PMID:
28318095
40.

NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53.

Cai Q, Tu M, Xu-Monette ZY, Sun R, Manyam GC, Xu X, Tzankov A, Hsi ED, Møller MB, Medeiros LJ, Ok CY, Young KH.

Mod Pathol. 2017 Jun;30(6):854-876. doi: 10.1038/modpathol.2017.5. Epub 2017 Mar 10.

41.

Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States.

Hsi ED, Horwitz SM, Carson KR, Pinter-Brown LC, Rosen ST, Pro B, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Collie AM, Gruver AM, Grzywacz BJ, Turakhia S, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM.

Clin Lymphoma Myeloma Leuk. 2017 Apr;17(4):193-200. doi: 10.1016/j.clml.2016.10.001. Epub 2017 Jan 10.

PMID:
28209473
42.

The Genetic Basis of Hepatosplenic T-cell Lymphoma.

McKinney M, Moffitt AB, Gaulard P, Travert M, De Leval L, Nicolae A, Raffeld M, Jaffe ES, Pittaluga S, Xi L, Heavican T, Iqbal J, Belhadj K, Delfau-Larue MH, Fataccioli V, Czader MB, Lossos IS, Chapman-Fredricks JR, Richards KL, Fedoriw Y, Ondrejka SL, Hsi ED, Low L, Weisenburger D, Chan WC, Mehta-Shah N, Horwitz S, Bernal-Mizrachi L, Flowers CR, Beaven AW, Parihar M, Baseggio L, Parrens M, Moreau A, Sujobert P, Pilichowska M, Evens AM, Chadburn A, Au-Yeung RK, Srivastava G, Choi WW, Goodlad JR, Aurer I, Basic-Kinda S, Gascoyne RD, Davis NS, Li G, Zhang J, Rajagopalan D, Reddy A, Love C, Levy S, Zhuang Y, Datta J, Dunson DB, Davé SS.

Cancer Discov. 2017 Apr;7(4):369-379. doi: 10.1158/2159-8290.CD-16-0330. Epub 2017 Jan 25.

43.

Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era.

Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, Mansur DB, Cherian S, Cooper BW, De Lima MJG, Lazarus HM, Gerson SL, Jagadeesh D, Smith MR, Dean RM, Pohlman BL, Hill BT, William BM.

Hematology. 2017 Aug;22(7):405-411. doi: 10.1080/10245332.2017.1279842. Epub 2017 Jan 20.

PMID:
28105889
44.

RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma.

Zhang M, Xu-Monette ZY, Li L, Manyam GC, Visco C, Tzankov A, Wang J, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Han van Krieken J, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Piris MA, Medeiros LJ, Pham LV, Young KH.

Aging (Albany NY). 2016 Dec 8;8(12):3321-3340. doi: 10.18632/aging.101121.

45.

A prospective cohort study of patients with peripheral T-cell lymphoma in the United States.

Carson KR, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta MA, Shustov AR, Advani RH, Feldman TA, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM.

Cancer. 2017 Apr 1;123(7):1174-1183. doi: 10.1002/cncr.30416. Epub 2016 Dec 2.

46.

Performance of a Commercially Available MAL Antibody in the Diagnosis of Primary Mediastinal Large B-Cell Lymphoma.

Gentry M, Bodo J, Durkin L, Hsi ED.

Am J Surg Pathol. 2017 Feb;41(2):189-194. doi: 10.1097/PAS.0000000000000771.

PMID:
27879516
47.

Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.

Xu-Monette ZY, Li L, Byrd JC, Jabbar KJ, Manyam GC, Maria de Winde C, van den Brand M, Tzankov A, Visco C, Wang J, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Wang M, Hagemeister FB, Piris MA, Han van Krieken J, Medeiros LJ, Li Y, van Spriel AB, Young KH.

Blood. 2016 Dec 29;128(26):3083-3100. doi: 10.1182/blood-2016-05-715094. Epub 2016 Oct 19.

48.

CAL2 Immunohistochemical Staining Accurately Identifies CALR Mutations in Myeloproliferative Neoplasms.

Nomani L, Bodo J, Zhao X, Durkin L, Loghavi S, Hsi ED.

Am J Clin Pathol. 2016 Oct;146(4):431-8. doi: 10.1093/ajcp/aqw135.

PMID:
27686170
49.

Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells.

Bodo J, Zhao X, Durkin L, Souers AJ, Phillips DC, Smith MR, Hsi ED.

Oncotarget. 2016 Oct 25;7(43):70000-70010. doi: 10.18632/oncotarget.12132.

50.

Clinical approach to diffuse large B cell lymphoma.

Caimi PF, Hill BT, Hsi ED, Smith MR.

Blood Rev. 2016 Nov;30(6):477-491. doi: 10.1016/j.blre.2016.06.003. Epub 2016 Jun 30. Review.

PMID:
27596109

Supplemental Content

Support Center